Tharimmune Inc (THAR)

$5.37 -0.11 (-2.01%)
Market Cap 184.50M
Revenue (ttm) 0.00
Net Income (ttm) -12.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,049,500
Avg Vol 752,792
Day's Range N/A - N/A
Shares Out 37.73M
Stochastic %K 85%
Beta 1.40
Analysts Strong Buy
Price Target $17.00

Company Profile

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States. It is involved in the development of TH104 for the proposed indication of temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with opioids, as well as is in phase 2 study in patients with chronic pruritus in primary bili...

Industry: Biotechnology
Sector: Healthcare
Phone: 732 889 3111
Address:
34 Shrewsbury Avenue, Suite 1C, Red Bank, United States
Stock_Catcher
Stock_Catcher Feb. 4 at 2:24 AM
Wealthy Wednesday Watchlist Pt 10 $BURU $THAR $ARDX $UAVS $RUM Let's Find a 1000% Runner this week
1 · Reply
Stock_Catcher
Stock_Catcher Feb. 4 at 1:53 AM
New Video out on the Bullish Analysis on $SOUN $UAVS $LNKS $RUM $THAR and more ! Let's Bank https://www.youtube.com/watch?v=zbCJDB4kNOY&lc=Ugw5OB6U1Cj63eIANCN4AaABAg
1 · Reply
AnomalyDetective
AnomalyDetective Feb. 3 at 12:58 PM
$TER beats big on earnings up +22.6% premarket while $THAR from Week 2 continues higher up +79% from January on the first positive signals in over a year. Credit: http://vmbreakouts.com @vmbreakouts More: https://x.com/jdhenning/status/2018670125227090316
0 · Reply
BODYBAG69
BODYBAG69 Feb. 3 at 10:25 AM
$THAR the fact that this keeps rallying despite nobody seemingly knowing how many $CC.X it holds or the total amount of shares outstanding (including warrants) is kinda wild. Also, it’s not like $CC.X is crazy trending anywhere to justify this thing being hyped.
1 · Reply
BODYBAG69
BODYBAG69 Feb. 2 at 11:28 PM
$THAR any idea the fully diluted amount of shares in this thing? You have the shares plus the warrants. My best guess is 180M. Anyone else have any idea?
0 · Reply
StockJelli
StockJelli Feb. 2 at 7:58 PM
A couple more gainers as we reach power hour. $THAR $TNYA $OPTX $ETHD $PKST
0 · Reply
topstockalerts
topstockalerts Feb. 2 at 7:27 PM
$THAR Following this closely as it continues to build momentum. Buyers are in control. Could be more upside ahead.
0 · Reply
Lucas_Ward_
Lucas_Ward_ Feb. 2 at 6:22 PM
$THAR illiquid microcap under the radar needs accumulation signal
0 · Reply
P4antomDock_144
P4antomDock_144 Feb. 2 at 6:18 PM
$THAR illiquid microcap under the radar needs accumulation signal
0 · Reply
SwingTradesOnly
SwingTradesOnly Feb. 2 at 3:18 PM
$THAR THAR, more like THOR. this mofo rolling
0 · Reply
Latest News on THAR
Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

Feb 2, 2026, 8:15 AM EST - 1 day ago

Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

Tharimmune Announces Expanded Role as Super Validator on Canton Network

Jan 26, 2026, 8:15 AM EST - 8 days ago

Tharimmune Announces Expanded Role as Super Validator on Canton Network

Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Jan 23, 2026, 12:34 AM EST - 11 days ago

Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering

Jan 22, 2026, 4:12 PM EST - 12 days ago

Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering

Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering

Jan 20, 2026, 8:45 AM EST - 14 days ago

Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering

Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network

Dec 18, 2025, 8:15 AM EST - 6 weeks ago

Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

Dec 12, 2025, 8:15 AM EST - 7 weeks ago

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Nov 13, 2025, 8:05 AM EST - 2 months ago

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Nov 6, 2025, 4:16 PM EST - 3 months ago

Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Nov 3, 2025, 9:04 AM EST - 3 months ago

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Sep 4, 2025, 8:01 AM EDT - 5 months ago

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Aug 20, 2025, 8:00 AM EDT - 5 months ago

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Aug 13, 2025, 8:01 AM EDT - 6 months ago

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Aug 5, 2025, 8:00 AM EDT - 6 months ago

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Aug 4, 2025, 8:00 AM EDT - 6 months ago

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Jul 23, 2025, 10:15 PM EDT - 6 months ago

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Jun 17, 2025, 8:01 AM EDT - 8 months ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025, 8:01 AM EDT - 9 months ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025, 8:01 AM EDT - 9 months ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 30, 2025, 8:01 AM EDT - 9 months ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 28, 2025, 8:01 AM EDT - 10 months ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 10 months ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Apr 7, 2025, 8:00 AM EDT - 10 months ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 24, 2025, 8:00 AM EDT - 11 months ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Mar 4, 2025, 7:00 AM EST - 1 year ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Tharimmune to Present at the Microcap Conference 2025

Jan 27, 2025, 8:30 AM EST - 1 year ago

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 16, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Dec 6, 2024, 4:15 PM EST - 1 year ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 18, 2024, 8:00 AM EST - 1 year ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 13, 2024, 8:00 AM EST - 1 year ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Nov 4, 2024, 9:00 AM EST - 1 year ago

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Oct 28, 2024, 9:00 AM EDT - 1 year ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 30, 2024, 8:31 AM EDT - 1 year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 23, 2024, 7:31 AM EDT - 1 year ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Mar 5, 2024, 8:31 AM EST - 2 years ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 20, 2024, 8:01 AM EST - 2 years ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Feb 5, 2024, 8:30 AM EST - 2 years ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Jan 29, 2024, 8:00 AM EST - 2 years ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Dec 11, 2023, 8:01 AM EST - 2 years ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Nov 30, 2023, 4:01 PM EST - 2 years ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Nov 27, 2023, 9:40 PM EST - 2 years ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Nov 27, 2023, 8:00 AM EST - 2 years ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Stock_Catcher
Stock_Catcher Feb. 4 at 2:24 AM
Wealthy Wednesday Watchlist Pt 10 $BURU $THAR $ARDX $UAVS $RUM Let's Find a 1000% Runner this week
1 · Reply
Stock_Catcher
Stock_Catcher Feb. 4 at 1:53 AM
New Video out on the Bullish Analysis on $SOUN $UAVS $LNKS $RUM $THAR and more ! Let's Bank https://www.youtube.com/watch?v=zbCJDB4kNOY&lc=Ugw5OB6U1Cj63eIANCN4AaABAg
1 · Reply
AnomalyDetective
AnomalyDetective Feb. 3 at 12:58 PM
$TER beats big on earnings up +22.6% premarket while $THAR from Week 2 continues higher up +79% from January on the first positive signals in over a year. Credit: http://vmbreakouts.com @vmbreakouts More: https://x.com/jdhenning/status/2018670125227090316
0 · Reply
BODYBAG69
BODYBAG69 Feb. 3 at 10:25 AM
$THAR the fact that this keeps rallying despite nobody seemingly knowing how many $CC.X it holds or the total amount of shares outstanding (including warrants) is kinda wild. Also, it’s not like $CC.X is crazy trending anywhere to justify this thing being hyped.
1 · Reply
BODYBAG69
BODYBAG69 Feb. 2 at 11:28 PM
$THAR any idea the fully diluted amount of shares in this thing? You have the shares plus the warrants. My best guess is 180M. Anyone else have any idea?
0 · Reply
StockJelli
StockJelli Feb. 2 at 7:58 PM
A couple more gainers as we reach power hour. $THAR $TNYA $OPTX $ETHD $PKST
0 · Reply
topstockalerts
topstockalerts Feb. 2 at 7:27 PM
$THAR Following this closely as it continues to build momentum. Buyers are in control. Could be more upside ahead.
0 · Reply
Lucas_Ward_
Lucas_Ward_ Feb. 2 at 6:22 PM
$THAR illiquid microcap under the radar needs accumulation signal
0 · Reply
P4antomDock_144
P4antomDock_144 Feb. 2 at 6:18 PM
$THAR illiquid microcap under the radar needs accumulation signal
0 · Reply
SwingTradesOnly
SwingTradesOnly Feb. 2 at 3:18 PM
$THAR THAR, more like THOR. this mofo rolling
0 · Reply
SpankerBanker
SpankerBanker Feb. 2 at 10:08 AM
$THAR it is a worthless distraction... short this crap
1 · Reply
BODYBAG69
BODYBAG69 Feb. 2 at 7:08 AM
$THAR for those of you buying this stock, how many $CC.X does the company hold? I can’t find it anywhere. I’d like some idea what the MNAV is.
1 · Reply
aquibtahseen
aquibtahseen Feb. 2 at 3:31 AM
$THAR hoping for double digit soon 🤞🏼
0 · Reply
Bryan5335
Bryan5335 Feb. 2 at 2:04 AM
$THAR let’s go!!! 6 comin!
0 · Reply
houstontrading
houstontrading Feb. 1 at 11:32 PM
$THAR looks like the shorts are running out of time. There's a bunch at 1 to 3 days. Im wondering if this is gonna rip!
0 · Reply
TonyStacks
TonyStacks Feb. 1 at 2:12 AM
$CC.X $THAR Positions in both. I have $XRP.X fatigue, moving to the sidelines for now
0 · Reply
TonyStacks
TonyStacks Feb. 1 at 2:07 AM
$THAR $CC I own both, moved off $XRP.X for now. Broke all levels of TA support.
0 · Reply
leon_dedrick
leon_dedrick Jan. 31 at 1:55 PM
$THAR Pretty soon, Canton Coin will be used as a store of value because of its burn/mint equilibrium As long as it's being used, the value grows, and by it being tied to the largest institutions and infrastructure in the US pretty much guarantees it's use
2 · Reply
RunnerSignals
RunnerSignals Jan. 30 at 9:35 PM
Red to Green Warriors you didn't see coming $PLX $THAR $ALT $IBRX $ACMR opened weak closed strong. classic shakeout then breakout action
0 · Reply
WesCoastAL
WesCoastAL Jan. 30 at 7:21 PM
$THAR this has been edging higher ☝️🙏
0 · Reply
JonBoyAlerts
JonBoyAlerts Jan. 30 at 7:20 PM
$THAR in
0 · Reply
annee33
annee33 Jan. 30 at 7:15 PM
$THAR I'm in, let er rip!
0 · Reply